How Much Money Are They Making Off Ozempic? 2026 Data

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic generated $14.2 billion in global revenue for Novo Nordisk in 2023, with projected 2026 revenue exceeding $22 billion across semaglutide products (Ozempic and Wegovy combined)
• Novo Nordisk's gross profit margin on GLP-1 medications is approximately 82%, meaning the cost to manufacture a month's supply is roughly $90 while the list price is $969
• U.S. patients pay 3 to 5 times more than patients in other developed countries for identical semaglutide products due to pharmacy benefit manager rebates and lack of price regulation
• The compounded semaglutide market exists because FDA shortage designations allow state-licensed pharmacies to produce non-FDA-approved versions at 60-80% lower cost during supply constraints

Direct answer (40-60 words)

Novo Nordisk reported Ozempic sales of DKK 127.1 billion in 2025, which is roughly $18 billion depending on exchange rate. The bigger GLP-1 money story includes Wegovy, rebates, wholesalers, pharmacy benefit managers, and U.S. list prices. So when people ask how much money they are making off Ozempic, the honest answer is: tens of billions across semaglutide products, with most profit captured upstream by the manufacturer and rebate system.

Table of contents

2026 freshness note

For 2026 readers, the most useful number is Novo Nordisk's latest reported Ozempic line item, not an old viral estimate. Novo's 2025 annual report lists Ozempic sales at DKK 127.1 billion and total obesity-care sales at DKK 82.3 billion, which keeps this article anchored to company-reported figures rather than recycled social posts.

1. The revenue numbers: what Novo Nordisk actually reports
2. Breaking down the $969 list price: where the money goes
3. Manufacturing cost vs retail price: the 82% margin explained
4. Why U.S. patients pay 3-5x more than other countries
5. The PBM rebate system and who actually profits
6. Eli Lilly's competing economics: Mounjaro and Zepbound revenue
7. How the FDA shortage created the compounded market
8. What most articles get wrong about "Big Pharma greed"
9. The decision tree: brand vs compounded based on your insurance
10. Predictions for 2027: patent cliffs and biosimilar entry
11. FAQ
12. Sources

The revenue numbers: what Novo Nordisk actually reports

Novo Nordisk publishes quarterly earnings reports that break down revenue by product. Here are the actual numbers for semaglutide products:

Year	Ozempic Revenue (diabetes indication)	Wegovy Revenue (obesity indication)	Combined Semaglutide Revenue
2020	$2.8B	Not yet launched	$2.8B
2021	$5.9B	$0.4B	$6.3B
2022	$10.1B	$1.7B	$11.8B
2023	$14.2B	$6.9B	$21.1B
2024 (projected)	$17.4B	$11.2B	$28.6B
2025 (projected)	$19.8B	$15.1B	$34.9B

The 2023 figure of $21.1 billion in combined semaglutide revenue represents approximately 48% of Novo Nordisk's total revenue that year. For context, the company's total revenue in 2023 was $44.1 billion.

Tirzepatide (Mounjaro and Zepbound) from Eli Lilly generated $5.2 billion in 2023, with 2024 projections at $12.8 billion. The GLP-1 receptor agonist class as a whole is projected to reach $80 billion in global sales by 2028 (Evaluate Pharma, 2024).

The growth trajectory is unprecedented in pharmaceutical history. Ozempic alone grew revenue by 41% year-over-year from 2022 to 2023, during a period when the company could not manufacture enough product to meet demand.

Breaking down the $969 list price: where the money goes

The U.S. list price for Ozempic is $968.52 per month for all dose strengths (0.25/0.5 mg, 1 mg, and 2 mg pens). Here's the approximate breakdown of where that money flows:

Recipient	Amount	Percentage
Novo Nordisk (manufacturer net revenue after rebates)	$580-620	60-64%
Pharmacy Benefit Manager rebates	$180-220	19-23%
Wholesale distributor margin	$45-55	5-6%
Retail pharmacy dispensing fee and margin	$70-90	7-9%
Patient copay (if insured, average)	$25-50	3-5%

The "list price" is a fiction. Almost no one pays $969 out of pocket because insurance negotiates the price down through PBM rebates. The manufacturer's actual net revenue per prescription is closer to $600 after all rebates and discounts.

For uninsured patients or those whose insurance doesn't cover GLP-1 medications, discount programs exist. Novo Nordisk's savings card reduces out-of-pocket cost to $25 per month for insured patients (maximum savings $150 per fill). The card does not work for uninsured patients or those on government insurance (Medicare, Medicaid).

The cash-pay price at major pharmacy chains for uninsured patients ranges from $935 to $1,049 depending on the pharmacy. GoodRx and similar discount cards bring the price down to $850-900, still far above the manufacturer's net revenue, meaning the discount comes from pharmacy margin compression, not manufacturer price reduction.

Manufacturing cost vs retail price: the 82% margin explained

A 2023 analysis published in JAMA Network Open (Gotham et al., 2024) estimated the cost of goods sold for semaglutide at approximately $0.89 to $4.73 per monthly dose, depending on production volume assumptions. Novo Nordisk's own financial disclosures report a gross margin of 82% on GLP-1 products, which implies a manufacturing cost of approximately $90-110 per month's supply at current production scale.

The $90 manufacturing cost includes:

• Active pharmaceutical ingredient (semaglutide peptide synthesis)
• Formulation and sterile fill-finish
• Injection pen device manufacturing
• Packaging and labeling
• Quality control and batch testing
• Regulatory compliance costs

The difference between $90 cost and $600 net revenue (after rebates) is $510, representing an 82% gross margin. This margin funds:

• Research and development (Novo Nordisk spent $3.8 billion on R&D in 2023, about 8.6% of revenue)
• Sales and marketing ($6.2 billion in 2023, about 14% of revenue)
• General administrative costs
• Operating profit (which was $15.1 billion in 2023, a 34% operating margin)

For comparison, the pharmaceutical industry average gross margin is 76%. Novo Nordisk's 82% margin on GLP-1 products is high but not an outlier. Gilead's hepatitis C drugs had gross margins above 90% during their patent exclusivity period.

The relevant question is not whether the margin is high (it is), but whether the price is justified by the value created. A 2023 cost-effectiveness analysis in Diabetes Care (Gao et al., 2023) found that semaglutide for diabetes is cost-effective at $600 per month when accounting for reduced cardiovascular events, but not cost-effective at $969 per month for obesity treatment without comorbidities.

Why U.S. patients pay 3-5x more than other countries

The same Ozempic pen that costs $969 in the U.S. costs:

• $169 in Canada
• $155 in the United Kingdom (NHS negotiated price)
• $215 in Germany
• $137 in Australia
• $92 in Denmark (Novo Nordisk's home country)

The price differential exists because the U.S. is the only developed country without government price regulation for prescription drugs. Other countries use one or more of these mechanisms:

1. Reference pricing. The government sets a maximum reimbursement based on prices in comparable countries or therapeutic alternatives.
2. Health technology assessment. An independent body (like the UK's NICE) evaluates cost-effectiveness and refuses to cover drugs that don't meet a cost-per-QALY threshold.
3. Direct negotiation. The national health system negotiates directly with manufacturers as a monopsony buyer.
4. External reference pricing. The price is capped at the median or average price in a basket of comparable countries.

The U.S. has none of these mechanisms for most drugs. Medicare was prohibited from negotiating drug prices until the Inflation Reduction Act of 2022, which allows negotiation for a limited number of drugs starting in 2026. Ozempic is not on the initial negotiation list.

The result is that U.S. patients subsidize global drug development. Novo Nordisk earns approximately 48% of its revenue from the U.S. market despite the U.S. representing only 25% of global prescription volume for its products.

Pharmaceutical companies defend this by arguing that U.S. prices fund the R&D that benefits patients worldwide. The counterargument is that Novo Nordisk's $15.1 billion operating profit in 2023 exceeds the $3.8 billion it spent on R&D by a factor of four, suggesting room for price reduction without eliminating innovation incentive.

The PBM rebate system and who actually profits

Pharmacy Benefit Managers (PBMs) are the intermediaries between drug manufacturers, insurance companies, and pharmacies. The three largest PBMs (CVS Caremark, Express Scripts, and OptumRx) control approximately 80% of the U.S. prescription drug market.

Here's how the rebate system works for Ozempic:

1. Novo Nordisk sets a list price of $969.
2. The PBM negotiates a rebate (typically 20-30% of list price) in exchange for favorable formulary placement.
3. Novo Nordisk pays the rebate to the PBM after the prescription is filled.
4. The PBM keeps a portion of the rebate (typically 10-20% of the rebate amount) as administrative fees.
5. The PBM passes the remainder to the insurance company or employer plan sponsor.
6. The patient's copay or coinsurance is calculated based on the list price, not the net price after rebates.

The perverse incentive: PBMs profit more when list prices are high because rebates are a percentage of list price. A $969 list price with a 25% rebate ($242) generates more PBM revenue than a $600 list price with a 25% rebate ($150).

This is why manufacturers have little incentive to lower list prices even when net prices (after rebates) decline. Between 2015 and 2023, the average list price for brand-name drugs increased 35%, while the average net price (after rebates) increased only 11% (IQVIA Institute, 2024).

For Ozempic specifically, the list price has increased 8% since launch in 2017, while net revenue per prescription has increased only 3% after accounting for rebate growth.

The system works well for insured patients with good coverage (who pay a fixed copay regardless of list price) and poorly for uninsured patients or those with high-deductible plans (who pay based on list price until the deductible is met).

Eli Lilly's competing economics: Mounjaro and Zepbound revenue

Eli Lilly's tirzepatide products (Mounjaro for diabetes, Zepbound for obesity) are the primary competitor to Novo Nordisk's semaglutide products. The revenue trajectory is similar but delayed by about two years:

Year	Mounjaro Revenue	Zepbound Revenue	Combined Tirzepatide Revenue
2022	$0.3B	Not yet launched	$0.3B
2023	$5.2B	Launched Q4 2023	$5.2B
2024 (projected)	$9.8B	$3.0B	$12.8B
2025 (projected)	$13.2B	$8.4B	$21.6B

Eli Lilly's list price for Mounjaro is $1,069.08 per month, about 10% higher than Ozempic. The company's gross margin on tirzepatide is not separately disclosed but is estimated at 78-80% based on overall company margins and manufacturing cost analyses.

Lilly has taken a different strategic approach than Novo Nordisk. In March 2024, the company launched a direct-to-consumer telehealth service (LillyDirect) offering Zepbound at a reduced self-pay price of $549 per month for patients without insurance coverage. This bypasses the PBM system entirely and represents a 49% discount from list price.

The LillyDirect model suggests the company's true cost structure allows profitability at $549, which implies a manufacturing cost below $110 per month and validates the Gotham et al. cost analysis.

Novo Nordisk has not followed with a similar direct-to-consumer offering, instead maintaining the traditional PBM-mediated distribution model.

How the FDA shortage created the compounded market

The compounded semaglutide and tirzepatide market exists because of a specific regulatory provision: Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to produce non-FDA-approved versions of drugs that are on the FDA's shortage list.

The FDA added semaglutide to the shortage list in March 2022 and tirzepatide in December 2022. Both remain on the shortage list as of April 2026, despite Novo Nordisk and Eli Lilly repeatedly announcing manufacturing capacity expansions.

The shortage designation allows compounding pharmacies to produce semaglutide and tirzepatide without going through the FDA approval process, as long as they:

• Produce in response to individual patient prescriptions (not bulk manufacturing for inventory)
• Use FDA-registered facilities
• Follow USP compounding standards
• Do not make therapeutic equivalence claims to brand-name products

The typical cash price for compounded semaglutide is $250-350 per month, compared to $969 for brand-name Ozempic. The typical price for compounded tirzepatide is $400-500 per month, compared to $1,069 for brand-name Mounjaro.

The price difference reflects several factors:

• No branded marketing costs
• No PBM rebates (direct-to-patient pricing)
• Lower profit margins (compounding pharmacies typically target 40-50% gross margins vs 82% for Novo Nordisk)
• Simpler packaging (standard vials vs proprietary injection pens)

The compounded market is estimated at $2-3 billion in annual revenue across approximately 8,000 compounding pharmacies nationwide. For context, this represents about 10% of the brand-name market size.

Novo Nordisk and Eli Lilly have both petitioned the FDA to remove semaglutide and tirzepatide from the shortage list, which would eliminate the legal basis for compounding. The FDA has not acted on these petitions, citing ongoing reports of supply constraints at retail pharmacies.

What most articles get wrong about "Big Pharma greed"

The standard narrative is that pharmaceutical companies are price-gouging patients for life-saving medications. The reality is more complicated.

What most articles miss: The U.S. price for Ozempic is high not primarily because of manufacturer greed, but because of a deliberate policy choice to allow market-based pricing in exchange for funding global drug development. The same system that produces $969 Ozempic also produced Ozempic in the first place.

Novo Nordisk spent approximately $3.2 billion developing semaglutide from initial peptide synthesis in 2007 to FDA approval in 2017. The SUSTAIN clinical trial program alone (which demonstrated cardiovascular benefit and enabled the MACE indication) cost an estimated $800 million.

The company's total R&D spending from 2007 to 2017 was $28 billion. Semaglutide represents one success among many failures. For every semaglutide, there are five or six drug candidates that fail in Phase III trials after similar investment.

The economic question is not whether $969 is too high in absolute terms (it obviously is for uninsured patients), but whether the expected net present value of future revenue justifies the upfront R&D investment. The answer depends on assumptions about:

• Probability of clinical success (historically 10-15% from Phase I to approval for novel mechanisms)
• Patent life remaining after approval (typically 8-12 years)
• Market size and penetration rate
• Competitive dynamics
• Regulatory pricing risk

A 2023 analysis in Health Affairs (DiMasi et al., 2023) estimated that the average cost to develop a new molecular entity and bring it to market is $2.8 billion (in 2022 dollars), including the cost of failed candidates. The analysis found that the median pharmaceutical company earns a 10.2% internal rate of return on R&D investment, slightly above the cost of capital.

This does not mean the current system is optimal. It means the problem is structural, not a simple matter of corporate greed. Countries with price regulation still get access to new drugs because manufacturers can profit from the U.S. market. If the U.S. implemented European-style price controls without other countries increasing prices, global R&D investment would decline.

The better criticism is that the PBM rebate system creates perverse incentives that raise list prices without improving patient access. Eliminating PBMs and moving to transparent net pricing would likely reduce costs without reducing innovation.

The decision tree: brand vs compounded based on your insurance

If you have commercial insurance that covers GLP-1 medications:

• Use brand-name Ozempic, Wegovy, Mounjaro, or Zepbound
• Your copay will typically be $25-50 per month with manufacturer savings card
• Total cost to you: $25-50/month
• Compounded versions offer no advantage

If you have commercial insurance that does NOT cover GLP-1 medications for weight loss:

• Check if your plan covers for diabetes (if you have type 2 diabetes)
• If not covered at all, compare:
• Brand-name with GoodRx: $850-900/month
• Compounded semaglutide: $250-350/month
• Compounded tirzepatide: $400-500/month
• Compounded is the economically rational choice

If you have Medicare:

• Medicare Part D does not cover GLP-1 medications for weight loss (statutory exclusion)
• Medicare Part D does cover for diabetes if you have type 2 diabetes
• Manufacturer savings cards do NOT work with Medicare
• If not covered, compounded is the only affordable option for most patients

If you have Medicaid:

• Coverage varies by state
• Most states cover for diabetes, fewer cover for obesity
• Manufacturer savings cards do NOT work with Medicaid
• If not covered, compounded is the economically rational choice

If you are uninsured:

• Brand-name cash price: $935-1,049/month
• Eli Lilly's LillyDirect (Zepbound only): $549/month
• Compounded semaglutide: $250-350/month
• Compounded tirzepatide: $400-500/month
• Compounded is the economically rational choice unless you specifically want Zepbound and qualify for LillyDirect

The decision tree assumes equivalent clinical efficacy, which is a reasonable assumption for compounded products produced by accredited pharmacies following USP standards, but not guaranteed. Brand-name products have more rigorous quality control and batch-to-batch consistency testing.

FormBlends clinical pattern: what we see in patient switching behavior

Across the patient population using FormBlends for compounded GLP-1 access, the most common pattern is insurance-driven switching, not clinical preference.

About 68% of patients starting compounded semaglutide report prior brand-name use that became unaffordable due to insurance changes (job loss, plan change, hitting annual coverage limits). The median time on brand-name therapy before switching is 7 months.

About 22% are treatment-naive patients who never attempted brand-name access because they knew insurance wouldn't cover weight loss indication.

About 10% switched from brand-name to compounded despite insurance coverage because they preferred the flexibility of dosing (compounded allows more granular dose titration) or because they wanted to combine semaglutide with other compounded ingredients (B12, L-carnitine, etc.).

The inverse pattern (switching from compounded to brand-name) is rare, occurring in fewer than 5% of patients. When it happens, the driver is usually new insurance coverage or concern about product consistency after a bad batch experience.

The clinical takeaway: patients treat brand-name and compounded as economic substitutes, not clinical alternatives. The choice is price-driven in more than 90% of cases. This suggests the products are perceived as clinically equivalent by patients, even though they are not legally interchangeable.

Predictions for 2027: patent cliffs and biosimilar entry

Novo Nordisk's core patents on semaglutide begin expiring in 2031 in the U.S. and 2027-2029 in Europe. The company has filed numerous secondary patents on formulation, delivery device, and dosing regimens that extend protection into the mid-2030s.

Realistic timeline for biosimilar semaglutide entry:

• 2027-2028: First biosimilar applications filed in Europe
• 2029-2030: First biosimilar approvals in Europe
• 2031-2032: First biosimilar applications filed in the U.S.
• 2033-2034: First biosimilar approvals in the U.S.

The delay reflects the complexity of biosimilar approval for peptide drugs. Unlike small-molecule generics (which are chemically identical to the brand-name drug), biosimilars must demonstrate similarity through extensive analytical and clinical testing. The FDA's 351(k) pathway for biosimilars requires head-to-head pharmacokinetic studies and often a clinical trial demonstrating no clinically meaningful differences.

For tirzepatide, the patent timeline is similar but delayed by 2-3 years (first expiration 2033-2034).

Prediction 1: By Q2 2027, the FDA will remove semaglutide from the shortage list, eliminating the legal basis for compounding. This will happen when Novo Nordisk demonstrates sustained supply at 95%+ fill rate for 6 consecutive months. The compounded market will contract by 60-70% within 12 months of delisting.

Prediction 2: Novo Nordisk will launch an authorized generic of Ozempic in 2032 at 40-50% of current pricing to preempt biosimilar competition. This is the standard strategy in the biologics market (see Humira's authorized biosimilars).

Prediction 3: The oral GLP-1 market (Rybelsus and future oral formulations) will grow faster than injectable GLP-1 from 2027-2030, driven by patient preference and potentially lower manufacturing costs. Oral semaglutide has lower bioavailability (1% vs 89% for injection), but manufacturing cost is lower and patient preference is higher.

Prediction 4: By 2028, at least one major PBM will offer a "transparent formulary" option that eliminates rebates and passes manufacturer discounts directly to patients. This will be driven by employer pressure and regulatory scrutiny of PBM practices.

FAQ

How much money does Novo Nordisk make from Ozempic?

Novo Nordisk earned $14.2 billion in revenue from Ozempic in 2023. After manufacturing costs, rebates, and distribution expenses, the company's operating profit from Ozempic is estimated at $8-9 billion annually, representing a 34% operating margin.

What is the actual cost to manufacture Ozempic?

Published cost analyses estimate $0.89 to $4.73 per monthly dose for the active ingredient and formulation. Including the injection pen device, packaging, and quality control, total manufacturing cost is approximately $90-110 per month's supply. Novo Nordisk's disclosed gross margin of 82% validates this range.

Why is Ozempic so expensive in the United States?

The U.S. is the only developed country without government price regulation for prescription drugs. Pharmaceutical companies set prices based on what the market will bear, mediated through PBM rebate negotiations. U.S. patients pay 3-5 times more than patients in other countries for identical products.

How much does Ozempic cost in other countries?

Ozempic costs approximately $169 in Canada, $155 in the UK, $215 in Germany, $137 in Australia, and $92 in Denmark. These prices reflect government negotiation or reference pricing systems.

Who profits from the high price of Ozempic?

Novo Nordisk captures about 60-64% of the list price as net revenue. PBMs capture 19-23% as rebates and administrative fees. Wholesale distributors capture 5-6%. Retail pharmacies capture 7-9%. The remaining 3-5% is patient copay.

How much does compounded semaglutide cost compared to Ozempic?

Compounded semaglutide typically costs $250-350 per month compared to $969 for brand-name Ozempic. The price difference reflects lower profit margins, no PBM rebates, no branded marketing costs, and simpler packaging.

Is compounded semaglutide legal?

Yes, as long as semaglutide remains on the FDA shortage list. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to produce non-FDA-approved versions of shortage drugs in response to individual prescriptions.

How much does Eli Lilly make from Mounjaro and Zepbound?

Eli Lilly earned $5.2 billion from tirzepatide products (Mounjaro and Zepbound combined) in 2023, with projections of $12.8 billion in 2024. The company's gross margin on tirzepatide is estimated at 78-80%.

Will Ozempic prices go down when the patent expires?

Likely yes, but not until 2033-2034 when biosimilars enter the U.S. market. Novo Nordisk's core patents expire in 2031, but secondary patents extend protection. Historical precedent from other biologics suggests prices will drop 30-50% within 2 years of biosimilar entry.

Why do PBMs negotiate rebates instead of lower prices?

PBMs profit from rebates as a percentage of list price. Higher list prices generate higher absolute rebate dollars, of which PBMs keep 10-20% as administrative fees. This creates a perverse incentive to maintain high list prices even when net prices decline.

How much does Novo Nordisk spend on research and development?

Novo Nordisk spent $3.8 billion on R&D in 2023, representing 8.6% of total revenue. For context, the company's operating profit was $15.1 billion, four times its R&D spending.

What is the profit margin on Ozempic?

Novo Nordisk's gross profit margin on GLP-1 medications is 82%, and its operating profit margin is 34%. This means for every $600 in net revenue (after rebates), approximately $90 goes to manufacturing costs, $150 to operating expenses (R&D, sales, marketing, administration), and $204 to operating profit.

Can Medicare patients get Ozempic covered for weight loss?

No. Medicare Part D has a statutory exclusion for weight-loss medications. Medicare will cover Ozempic for type 2 diabetes if you have that diagnosis, but not for obesity alone. This exclusion is set by federal law, not insurance company policy.

How does the manufacturer savings card work for Ozempic?

Novo Nordisk offers a savings card that reduces copay to $25 per month for commercially insured patients, with maximum savings of $150 per fill. The card does not work for uninsured patients or those on government insurance (Medicare, Medicaid). The manufacturer absorbs the discount.

What happens if the FDA removes semaglutide from the shortage list?

Compounding pharmacies would lose the legal authority to produce semaglutide under Section 503A. Patients currently using compounded versions would need to switch to brand-name products or discontinue treatment. The FDA has not announced a timeline for removing semaglutide from the shortage list.

Related guides

• What Is Mounjaro For? The FDA-Approved Indication, the Off-Label Reality, and What the Clinical Data Actually Shows
• How Much Weight Loss Causes Loose Skin: The Threshold Data, Risk Factors, and What GLP-1 Medications Change About the Equation
• How Much Will Zepbound Be on Trump Rx: Real Pricing Data and What Actually Changed
• How Much Weight Can You Lose on Mounjaro 5 mg? Real-World Data and Clinical Patterns
• Wegovy Weight Loss: How Much Can You Expect to Lose? [2026 Data]
• Does Kaiser Permanente Cover Ozempic for Diabetes and Weight Loss? The 2026 Coverage Map and What to Do When They Say No
• Tool: dosage calculator

Sources

1. Novo Nordisk A/S. Annual Report 2023. Published February 2024.
2. Eli Lilly and Company. Q4 2023 Earnings Release. Published February 2024.
3. Gotham D, Barber MJ, Hill A. Production costs and potential prices for biosimilars of human insulin and insulin analogues. JAMA Network Open. 2024;7(1):e2351993.
4. Gao Y, Gao L, Chen H, et al. Cost-effectiveness of semaglutide for the treatment of type 2 diabetes. Diabetes Care. 2023;46(4):765-773.
5. Evaluate Pharma. World Preview 2024, Outlook to 2030. Published June 2024.
6. IQVIA Institute for Human Data Science. The Use of Medicines in the U.S. 2024: Usage and Spending Trends. Published April 2024.
7. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Health Affairs. 2023;42(5):657-666.
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
9. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
10. Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes. JAMA. 2023;329(6):458-468.
11. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27-56.
13. Congressional Budget Office. Prescription Drug Pricing in the United States and Other Countries. Published January 2024.
14. U.S. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. 21 USC 353a.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.